Progress

2018-05-17 17:20:05 0

Nonalcoholic Fatty Liver Disease(NAFLD) is about to become the most common liver disease in the world and China, what’s more, there are no drugs for Nonalcoholic Steatohepatitis(NASH) at home and abroad. Sciwind Biosciences is committed to develop new medicines which treat fatty hepatitis by three pathways of reducing liver fat, inflammation and fibrosis. Several products have entered the CMC stage.


Sciwind Biosciences Drug Development Pipeline

图片.png